BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

39 related articles for article (PubMed ID: 12070006)

  • 1. Time to post-remission therapy is an independent prognostic factor in adults with acute lymphoblastic leukemia.
    Advani AS; Jin T; Ramsingh G; Tiu R; Saber W; Theil K; Sobecks R; Sekeres M; Copelan E; Sungren S; Tripp B; Kalaycio M
    Leuk Lymphoma; 2008 Aug; 49(8):1560-6. PubMed ID: 18766970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The prognostic significance of proportion of blasts in bone marrow on day 14 during induction chemotherapy in patients with adult Ph-negative acute lymphoblastic leukemia].
    Jia JS; Yang SM; Wang J; Jiang H; Zhao T; Bao L; Shi HX; Lu J; Zhu HH; Lai YY; Jiang B; Huang XJ; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2016 Jun; 37(6):497-502. PubMed ID: 27431075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia.
    Dai H; Zhang W; Li X; Han Q; Guo Y; Zhang Y; Wang Y; Wang C; Shi F; Zhang Y; Chen M; Feng K; Wang Q; Zhu H; Fu X; Li S; Han W
    Oncoimmunology; 2015 Nov; 4(11):e1027469. PubMed ID: 26451310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results of treatment of advanced-stage lymphoblastic lymphoma at St Jude Children's Research Hospital from 1962 to 2002.
    Sandlund JT; Pui CH; Zhou Y; Onciu M; Campana D; Hudson MM; Inaba H; Metzger ML; Bhojwani D; Ribeiro RC
    Ann Oncol; 2013 Sep; 24(9):2425-9. PubMed ID: 23788752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the ALL-BFM 95 trial: differential effects in precursor B-cell and T-cell leukemia.
    Lauten M; Möricke A; Beier R; Zimmermann M; Stanulla M; Meissner B; Odenwald E; Attarbaschi A; Niemeyer C; Niggli F; Riehm H; Schrappe M
    Haematologica; 2012 Jul; 97(7):1048-56. PubMed ID: 22271901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progress of minimal residual disease studies in childhood acute leukemia.
    Campana D
    Curr Hematol Malig Rep; 2010 Jul; 5(3):169-76. PubMed ID: 20467922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of minimal residual disease evaluation in leukemia therapy.
    Campana D
    Curr Hematol Malig Rep; 2008 Jul; 3(3):155-60. PubMed ID: 20425460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of minimal residual disease monitoring in adult and pediatric acute lymphoblastic leukemia.
    Campana D
    Hematol Oncol Clin North Am; 2009 Oct; 23(5):1083-98, vii. PubMed ID: 19825454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-risk childhood acute lymphoblastic leukemia.
    Bhojwani D; Howard SC; Pui CH
    Clin Lymphoma Myeloma; 2009; 9 Suppl 3(Suppl 3):S222-30. PubMed ID: 19778845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effective treatment of advanced-stage childhood lymphoblastic lymphoma without prophylactic cranial irradiation: results of St Jude NHL13 study.
    Sandlund JT; Pui CH; Zhou Y; Behm FG; Onciu M; Razzouk BI; Hijiya N; Campana D; Hudson MM; Ribeiro RC
    Leukemia; 2009 Jun; 23(6):1127-30. PubMed ID: 19194463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of age, leukocyte count and day 21-bone marrow response to chemotherapy on the long-term outcome of children with philadelphia chromosome-positive acute lymphoblastic leukemia in the pre-imatinib era: results of the FRALLE 93 study.
    Gandemer V; Auclerc MF; Perel Y; Vannier JP; Le Gall E; Demeocq F; Schmitt C; Piguet C; Stephan JL; Lejars O; Debre M; Jonveaux P; Cayuela JM; Chevret S; Leverger G; Baruchel A;
    BMC Cancer; 2009 Jan; 9():14. PubMed ID: 19144139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Status of minimal residual disease testing in childhood haematological malignancies.
    Campana D
    Br J Haematol; 2008 Nov; 143(4):481-9. PubMed ID: 18710378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01.
    Zhou J; Goldwasser MA; Li A; Dahlberg SE; Neuberg D; Wang H; Dalton V; McBride KD; Sallan SE; Silverman LB; Gribben JG;
    Blood; 2007 Sep; 110(5):1607-11. PubMed ID: 17485550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A set of genes that regulate cell proliferation predicts treatment outcome in childhood acute lymphoblastic leukemia.
    Flotho C; Coustan-Smith E; Pei D; Cheng C; Song G; Pui CH; Downing JR; Campana D
    Blood; 2007 Aug; 110(4):1271-7. PubMed ID: 17456722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: a report from Children's Oncology Group Study P9201.
    Chauvenet AR; Martin PL; Devidas M; Linda SB; Bell BA; Kurtzberg J; Pullen J; Pettenati MJ; Carroll AJ; Shuster JJ; Camitta B
    Blood; 2007 Aug; 110(4):1105-11. PubMed ID: 17442849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A simplified flow cytometric assay identifies children with acute lymphoblastic leukemia who have a superior clinical outcome.
    Coustan-Smith E; Ribeiro RC; Stow P; Zhou Y; Pui CH; Rivera GK; Pedrosa F; Campana D
    Blood; 2006 Jul; 108(1):97-102. PubMed ID: 16537802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunologic monitoring in adults with acute lymphoblastic leukemia.
    Vidriales MB; Orfao A; San-Miguel JF
    Curr Oncol Rep; 2003 Sep; 5(5):413-8. PubMed ID: 12895394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistence of lymphoblasts in bone marrow on day 15 and days 22 to 25 of remission induction predicts a dismal treatment outcome in children with acute lymphoblastic leukemia.
    Sandlund JT; Harrison PL; Rivera G; Behm FG; Head D; Boyett J; Rubnitz JE; Gajjar A; Raimondi S; Ribeiro R; Hudson M; Relling M; Evans W; Pui CH
    Blood; 2002 Jul; 100(1):43-7. PubMed ID: 12070006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prognostic value of both detection of lymphoblasts in the period of early treatment and minimal residual disease in childhood acute lymphoblastic leukemia].
    Tie LJ; Gu LJ; Song DL; Jiang LM; Xue HL; Tang JY; Dong L; Pan C; Chen J; Ye H; Wang YP; Chen J
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):6-9. PubMed ID: 15946500
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.